deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03270059

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS

Sponsor: Celgene Corporation

Conditions Central Nervous System Neoplasm Cranial Nerve Disorder Metastatic Malignant Neoplasm in the Brain
Interventions Ferumoxytol Gadolinium Magnetic Resonance Imaging
Updated 16 times since 2017 Last updated: Feb 25, 2026 Started: Oct 6, 2017 Primary completion: Dec 15, 2027 Completion: Dec 15, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03270059, this PHASE2 trial focuses on Central Nervous System Neoplasm and Cranial Nerve Disorder and remains actively recruiting participants. Sponsored by Celgene Corporation, it has been updated 16 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2017 – ~Feb 2018 · 5 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Mar 2020 · 17 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshot~Nov 2021 – ~Jul 2022 · 8 months · monthly snapshot~Jul 2022 – ~Mar 2023 · 8 months · monthly snapshot~Mar 2023 – ~Sep 2023 · 6 months · monthly snapshot~Sep 2023 – ~Apr 2024 · 7 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Feb 2026 · 11 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

16 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

  2. Mar 2025 — Feb 2026 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Mar 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 11 earlier versions

  1. Sep 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

  2. Mar 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  3. Jul 2022 — Mar 2023 [monthly]

    Recruiting PHASE2

  4. Nov 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  5. May 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  7. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Oct 2018 — Mar 2020 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  10. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Sep 2017 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene Corporation
  • OHSU Knight Cancer Institute
  • Oregon Health and Science University
Data source: OHSU Knight Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations